Biohacking startups are pioneering ways to enhance human potential through genetic testing and nootropics. These companies blend neuroscience with personalized tech to boost cognitive and physical performance.
Genetic Testing Leaders
Companies like 23andMe and Helix lead with at-home DNA kits revealing health risks, ancestry, and traits. Users gain actionable insights, such as predispositions to cognitive decline, enabling tailored biohacking protocols. Helix partners with apps for ongoing genetic data analysis, turning raw sequences into daily optimization plans.
Nootropics and Neuroscience Backing
Nootropics—cognitive enhancers like racetams or adaptogens—are central to biohacking firms such as Nootrobox (now HVMN). Neuroscience research shows these compounds improve focus by modulating neurotransmitters like dopamine. Startups like Orig3n use genetic profiles to customize nootropic stacks, maximizing efficacy while minimizing side effects.
Emerging Biotech Innovators
Nebula Genomics offers whole-genome sequencing with blockchain privacy, empowering users to monetize data for research. BillionToOne advances prenatal and oncology diagnostics via cell-free DNA, extending to performance genetics. These firms raised millions, signaling investor confidence in biohacking’s trillion-dollar potential.
Key Applications in Performance
| Startup | Focus Area | Neuroscience Link |
|---|---|---|
| 23andMe | Ancestry & Health Risks | Identifies gene variants for brain health |
| Helix | Wellness & App Integration | Supports personalized nootropic dosing |
| Orig3n | Regenerative Treatments | Tailors stem cell therapies via genetics |
| Nebula | Blockchain Genome Storage | Enables secure data for cognitive studies |
Business Models and Growth
Startups monetize via subscriptions for ongoing testing and AI-driven recommendations. Funding exceeds $1 billion across leaders, with VCs like Andreessen Horowitz betting on longevity tech. Ethical concerns around data privacy persist, but CLIA/FDA certifications build trust.
Future of Personal Optimization
By 2026, expect AI-gene editing hybrids from firms like Tune Therapeutics to fine-tune epigenetics for peak performance. This fusion of science and business promises democratized superhuman abilities, grounded in peer-reviewed studies on neuroplasticity.